Entera Bio Files Prospectus For Resale Of Up To 134,803,910 Ordinary Shares By Selling Shareholders From July Private Placement
https://www.sec.gov/Archives/edgar/data/1638097/000117891326004221/zk2635989.htm
Read original at benzingaStocks · News reference
8-K filing — Entera Bio Ltd. (ENTX)
Filed: 2026-08-07 AccNo: 0001178913-26-003946 Size: 257 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 7, 2026, 8:06 PM
- Checked
- Aug 7, 2026, 8:06 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Entera Bio Ltd. (ENTX)
Filed: 2026-08-18 AccNo: 0001178913-26-004178 Size: 223 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarEntera Bio Q2 EPS $(0.14) Misses $(0.08) Estimate
Read original at benzingaEntera Bio Intends To File Ind For EB612 In First Half Of 2027; EB613 Phase 3 Study Initiation Planned For Late 2026, Topline Data Anticipated In Second Half 2028
IND Enabling Studies Ongoing for EB612 - the First Oral Peptide Replacement Tablet in Development for Patients with Hypoparathyroidism – Intention to File IND in First Half of 2027
Read original at benzinga